Report Detail

Pharma & Healthcare Global Neurometabolic Disorders Market Size, Status and Forecast 2019-2025

  • RnM3811753
  • |
  • 11 October, 2019
  • |
  • Global
  • |
  • 127 Pages
  • |
  • QYResearch
  • |
  • Pharma & Healthcare

This report focuses on the global Neurometabolic Disorders status, future forecast, growth opportunity, key market and key players. The study objectives are to present the Neurometabolic Disorders development in North America, Europe, China, Japan, Southeast Asia, India and Central & South America.

The key players covered in this study
Amicus Therapeutics
ISU Abxis
JCR Pharmaceuticals
Biosidus
Greenovation Biotech
UAB Proforma
Dong-A Socio Group
ExSAR Corporation
Lixte Biotechnology
Neuraltus Pharmaceuticals
Protalix
Pharming Group
Protalix BioTherapeutics
Amicus
Biomarin
Genzyme
Shire
Greencross

Market segment by Type, the product can be split into
Gaucher’s Disease
Fabry Disease
Pompe Disease
Mucopolysaccharidosis VI
Other

Market segment by Application, split into
Oral
Parenteral

Market segment by Regions/Countries, this report covers
North America
Europe
China
Japan
Southeast Asia
India
Central & South America

The study objectives of this report are:
To analyze global Neurometabolic Disorders status, future forecast, growth opportunity, key market and key players.
To present the Neurometabolic Disorders development in North America, Europe, China, Japan, Southeast Asia, India and Central & South America.
To strategically profile the key players and comprehensively analyze their development plan and strategies.
To define, describe and forecast the market by product type, market and key regions.

In this study, the years considered to estimate the market size of Neurometabolic Disorders are as follows:
History Year: 2014-2018
Base Year: 2018
Estimated Year: 2019
Forecast Year 2019 to 2025
For the data information by region, company, type and application, 2018 is considered as the base year. Whenever data information was unavailable for the base year, the prior year has been considered.


Table of Contents

    1 Report Overview

    • 1.1 Study Scope
    • 1.2 Key Market Segments
    • 1.3 Players Covered
    • 1.4 Market Analysis by Type
      • 1.4.1 Global Neurometabolic Disorders Market Size Growth Rate by Type (2014-2025)
      • 1.4.2 Gaucher’s Disease
      • 1.4.3 Fabry Disease
      • 1.4.4 Pompe Disease
      • 1.4.5 Mucopolysaccharidosis VI
      • 1.4.6 Other
    • 1.5 Market by Application
      • 1.5.1 Global Neurometabolic Disorders Market Share by Application (2019-2025)
      • 1.5.2 Oral
      • 1.5.3 Parenteral
    • 1.6 Study Objectives
    • 1.7 Years Considered

    2 Global Growth Trends

    • 2.1 Neurometabolic Disorders Market Size
    • 2.2 Neurometabolic Disorders Growth Trends by Regions
      • 2.2.1 Neurometabolic Disorders Market Size by Regions (2019-2025)
      • 2.2.2 Neurometabolic Disorders Market Share by Regions (2014-2019)
    • 2.3 Industry Trends
      • 2.3.1 Market Top Trends
      • 2.3.2 Market Drivers
      • 2.3.3 Market Challenges
      • 2.3.4 Porter’s Five Forces Analysis

    3 Market Share by Key Players

    • 3.1 Neurometabolic Disorders Market Size by by Players
      • 3.1.1 Global Neurometabolic Disorders Revenue by by Players (2014-2019)
      • 3.1.2 Global Neurometabolic Disorders Revenue Market Share by by Players (2014-2019)
      • 3.1.3 Global Neurometabolic Disorders Market Concentration Ratio (CR5 and HHI)
    • 3.2 Neurometabolic Disorders Key Players Head office and Area Served
    • 3.3 Key Players Neurometabolic Disorders Product/Solution/Service
    • 3.4 Date of Enter into Neurometabolic Disorders Market
    • 3.5 Mergers & Acquisitions, Expansion Plans

    4 Breakdown Data by Type and Application

    • 4.1 Global Neurometabolic Disorders Market Size by Type (2014-2019)
    • 4.2 Global Neurometabolic Disorders Market Size by Application (2014-2019)

    5 North America

    • 5.1 North America Neurometabolic Disorders Market Size (2014-2019)
    • 5.2 Neurometabolic Disorders Key Players in North America
    • 5.3 North America Neurometabolic Disorders Market Size by Type
    • 5.4 North America Neurometabolic Disorders Market Size by Application

    6 Europe

    • 6.1 Europe Neurometabolic Disorders Market Size (2014-2019)
    • 6.2 Neurometabolic Disorders Key Players in Europe
    • 6.3 Europe Neurometabolic Disorders Market Size by Type
    • 6.4 Europe Neurometabolic Disorders Market Size by Application

    7 China

    • 7.1 China Neurometabolic Disorders Market Size (2014-2019)
    • 7.2 Neurometabolic Disorders Key Players in China
    • 7.3 China Neurometabolic Disorders Market Size by Type
    • 7.4 China Neurometabolic Disorders Market Size by Application

    8 Japan

    • 8.1 Japan Neurometabolic Disorders Market Size (2014-2019)
    • 8.2 Neurometabolic Disorders Key Players in Japan
    • 8.3 Japan Neurometabolic Disorders Market Size by Type
    • 8.4 Japan Neurometabolic Disorders Market Size by Application

    9 Southeast Asia

    • 9.1 Southeast Asia Neurometabolic Disorders Market Size (2014-2019)
    • 9.2 Neurometabolic Disorders Key Players in Southeast Asia
    • 9.3 Southeast Asia Neurometabolic Disorders Market Size by Type
    • 9.4 Southeast Asia Neurometabolic Disorders Market Size by Application

    10 India

    • 10.1 India Neurometabolic Disorders Market Size (2014-2019)
    • 10.2 Neurometabolic Disorders Key Players in India
    • 10.3 India Neurometabolic Disorders Market Size by Type
    • 10.4 India Neurometabolic Disorders Market Size by Application

    11 Central & South America

    • 11.1 Central & South America Neurometabolic Disorders Market Size (2014-2019)
    • 11.2 Neurometabolic Disorders Key Players in Central & South America
    • 11.3 Central & South America Neurometabolic Disorders Market Size by Type
    • 11.4 Central & South America Neurometabolic Disorders Market Size by Application

    12 International Players Profiles

    • 12.1 Amicus Therapeutics
      • 12.1.1 Amicus Therapeutics Company Details
      • 12.1.2 Company Description and Business Overview
      • 12.1.3 Neurometabolic Disorders Introduction
      • 12.1.4 Amicus Therapeutics Revenue in Neurometabolic Disorders Business (2014-2019))
      • 12.1.5 Amicus Therapeutics Recent Development
    • 12.2 ISU Abxis
      • 12.2.1 ISU Abxis Company Details
      • 12.2.2 Company Description and Business Overview
      • 12.2.3 Neurometabolic Disorders Introduction
      • 12.2.4 ISU Abxis Revenue in Neurometabolic Disorders Business (2014-2019)
      • 12.2.5 ISU Abxis Recent Development
    • 12.3 JCR Pharmaceuticals
      • 12.3.1 JCR Pharmaceuticals Company Details
      • 12.3.2 Company Description and Business Overview
      • 12.3.3 Neurometabolic Disorders Introduction
      • 12.3.4 JCR Pharmaceuticals Revenue in Neurometabolic Disorders Business (2014-2019)
      • 12.3.5 JCR Pharmaceuticals Recent Development
    • 12.4 Biosidus
      • 12.4.1 Biosidus Company Details
      • 12.4.2 Company Description and Business Overview
      • 12.4.3 Neurometabolic Disorders Introduction
      • 12.4.4 Biosidus Revenue in Neurometabolic Disorders Business (2014-2019)
      • 12.4.5 Biosidus Recent Development
    • 12.5 Greenovation Biotech
      • 12.5.1 Greenovation Biotech Company Details
      • 12.5.2 Company Description and Business Overview
      • 12.5.3 Neurometabolic Disorders Introduction
      • 12.5.4 Greenovation Biotech Revenue in Neurometabolic Disorders Business (2014-2019)
      • 12.5.5 Greenovation Biotech Recent Development
    • 12.6 UAB Proforma
      • 12.6.1 UAB Proforma Company Details
      • 12.6.2 Company Description and Business Overview
      • 12.6.3 Neurometabolic Disorders Introduction
      • 12.6.4 UAB Proforma Revenue in Neurometabolic Disorders Business (2014-2019)
      • 12.6.5 UAB Proforma Recent Development
    • 12.7 Dong-A Socio Group
      • 12.7.1 Dong-A Socio Group Company Details
      • 12.7.2 Company Description and Business Overview
      • 12.7.3 Neurometabolic Disorders Introduction
      • 12.7.4 Dong-A Socio Group Revenue in Neurometabolic Disorders Business (2014-2019)
      • 12.7.5 Dong-A Socio Group Recent Development
    • 12.8 ExSAR Corporation
      • 12.8.1 ExSAR Corporation Company Details
      • 12.8.2 Company Description and Business Overview
      • 12.8.3 Neurometabolic Disorders Introduction
      • 12.8.4 ExSAR Corporation Revenue in Neurometabolic Disorders Business (2014-2019)
      • 12.8.5 ExSAR Corporation Recent Development
    • 12.9 Lixte Biotechnology
      • 12.9.1 Lixte Biotechnology Company Details
      • 12.9.2 Company Description and Business Overview
      • 12.9.3 Neurometabolic Disorders Introduction
      • 12.9.4 Lixte Biotechnology Revenue in Neurometabolic Disorders Business (2014-2019)
      • 12.9.5 Lixte Biotechnology Recent Development
    • 12.10 Neuraltus Pharmaceuticals
      • 12.10.1 Neuraltus Pharmaceuticals Company Details
      • 12.10.2 Company Description and Business Overview
      • 12.10.3 Neurometabolic Disorders Introduction
      • 12.10.4 Neuraltus Pharmaceuticals Revenue in Neurometabolic Disorders Business (2014-2019)
      • 12.10.5 Neuraltus Pharmaceuticals Recent Development
    • 12.11 Protalix
    • 12.12 Pharming Group
    • 12.13 Protalix BioTherapeutics
    • 12.14 Amicus
    • 12.15 Biomarin
    • 12.16 Genzyme
    • 12.17 Shire
    • 12.18 Greencross

    13 Market Forecast 2019-2025

    • 13.1 Market Size Forecast by Product (2019-2025)
    • 13.2 Market Size Forecast by Application (2019-2025)
    • 13.3 Market Size Forecast by Regions
    • 13.4 North America
    • 13.5 Europe
    • 13.6 China
    • 13.7 Japan
    • 13.8 Southeast Asia
    • 13.9 India
    • 13.10 Central & South America

    14 Analyst's Viewpoints/Conclusions

      15 Appendix

      • 15.1 Research Methodology
        • 15.1.1 Methodology/Research Approach
          • 15.1.1.1 Research Programs/Design
          • 15.1.1.2 Market Size Estimation
          • 15.1.1.3 Market Breakdown and Data Triangulation
        • 15.1.2 Data Source
          • 15.1.2.1 Secondary Sources
          • 15.1.2.2 Primary Sources
      • 15.2 Disclaimer

      Summary:
      Get latest Market Research Reports on Neurometabolic Disorders. Industry analysis & Market Report on Neurometabolic Disorders is a syndicated market report, published as Global Neurometabolic Disorders Market Size, Status and Forecast 2019-2025. It is complete Research Study and Industry Analysis of Neurometabolic Disorders market, to understand, Market Demand, Growth, trends analysis and Factor Influencing market.

      Last updated on

      REPORT YOU MIGHT BE INTERESTED

      Purchase this Report

      $3,900.00
      $5,850.00
      $7,800.00
      3,088.80
      4,633.20
      6,177.60
      3,603.60
      5,405.40
      7,207.20
      590,031.00
      885,046.50
      1,180,062.00
      325,143.00
      487,714.50
      650,286.00
      Credit card Logo

      Related Reports


      Reason to Buy

      Request for Sample of this report